Sponsor Dossier
Lupin
Sponsor Dossier for Lupin. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABACAVIR/LAMIVUDINE
- Brand: AMLODIPINE-LUPIN
- Brand: APIXABAN
- Brand: APO-LANSOPRAZOLE ODT
- Brand: ARX-FENOFIBRATE
- Brand: ARX-GLICLAZIDE
- Brand: ARX-MOXONIDINE
- Brand: Bella
About
Lupin is an Australian Private Company with ABN 97 112 038 105, registered in Victoria. The entity status is active.
Portfolio
Lupin maintains 68 brands on the ARTG, of which 39 have cleared the SEO quality gate for indexing. The portfolio includes 38 brands with Product Information on file, 2 brands with at least one PBS-listed item, and 4 brands with PBAC outcomes on record. No brands currently have AusPARs on record.
Therapeutic focus
The portfolio spans fourteen therapeutic areas as follows: — Neurology: 20 brands — Cardiology: 14 brands — Infectious Disease: 8 brands — Women's Health: 7 brands — Reproductive Health: 5 brands — Endocrinology: 4 brands — Urology: 2 brands — Oncology: 2 brands — Psychiatry: 1 brand — Pain & Anaesthesia: 1 brand — Immunology: 1 brand — Ophthalmology: 1 brand — Respiratory: 1 brand — Haematology: 1 brand
PBS footprint
Two brands in the Lupin portfolio are PBS-listed, with the latest PBS schedule date touched on 1 May 2026.
Regulatory activity
The most recent PBAC outcome for the portfolio dates to 1 November 2021, with four brands holding PBAC outcomes on record.